Immuron

Immuron is a biotechnology company based in Melbourne, Australia.[1] In 2008, The company changed its name and is now known as "Immuron Lt"

primarily focused on antigen-primed as well as dairy-derived health products, Immuron's proprietary technologies allow a rapid development for polyclonal antibody and other proteins-based solutions to a range of important diseases.

Immuron specialises in nutraceutical, pharmaceutical and related therapeutic technology products, including oral and GI mucositis, avian influenza, E. coli travellers' diarrhoea (TD), irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and Anthrax containment.

In 2005, Anadis signed an agreement with Quebec's Baralex Inc. and Valeo Pharma Inc. for the distribution of Travelan, a product made by Anadis for the Canadian market.[2]

References
  1. "Anadis". Australian Stock Exchange. 5 June 2007.
  2. Canada, Asia Pacific Foundation of. "Valeo Pharma, Baralex Sign Distribution Agreement with Australia's Anadis Ltd". Asia Pacific Foundation of Canada. Retrieved 18 September 2017.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.